Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CKS1B | P61024 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25191894 | 0.95 | HPGD (0.45) | SMN1; SMN2LMNAMEN1KMT2ANPSR1 | |
| SCHEMBL10186558 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAMEN1KMT2ANPSR1 | |
| SCHEMBL25173709 | 0.76 | USP30 (0.48) | SMN1; SMN2LMNAMEN1KMT2AMAPK1 | |
| SCHEMBL14114421 | 0.74 | USP2 (0.51) | SMN1; SMN2MEN1KMT2AHPGDMAPK1 | |
| SCHEMBL40106 | 0.74 | USP2 (0.51) | SMN1; SMN2MEN1KMT2AHPGDMAPK1 | |
| Ammonia Solution, Strong SCHEMBL19410300 | 0.72 | HPGD (0.50) | SMN1; SMN2MEN1KMT2AHPGDMAPK1 | |
| SCHEMBL22931754 | 0.72 | HPGD (0.50) | SMN1; SMN2MEN1KMT2AHPGDMAPK1 | |
| Benzene SCHEMBL29155321 | 0.72 | USP2 (0.53) | SMN1; SMN2MEN1KMT2AHPGDMAPK1 | |
| SCHEMBL7620463 | 0.71 | MEN1 (0.50) | SMN1; SMN2MEN1KMT2AHPGDMAPK1 | |
| SCHEMBL6350119 | 0.70 | USP2 (0.55) | SMN1; SMN2MEN1KMT2AHPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250018051-A1 | ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-01-16 | — | — | US | disclosed |
| EP-4429707-A1 | ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS | Nerviano Medical Sciences S.r.l. (IT) | 2024-09-18 | — | — | EP | disclosed |
| CN-118215506-A | Anthracycline derivative linker reagent, antibody-drug conjugate and method | 内尔维亚诺医疗科学公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2023083716-A1 | ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023083716-A1 | ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-05-19 | — | — | WO | disclosed |
| EP-4180061-A1 | ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS | Nerviano Medical Sciences S.r.l. (IT) | 2023-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250018051-A1 | ANTHRACYCLINE DERIVATIVE LINKER REAGENTS, ANTIBODY-DRUG CONJUGATES AND METHODS | DCTD, BCR, DUT | SMN1; SMN2 3612/4885LMNA 1694/4885MEN1 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.